Gensight Biologics (LTS:0RIM) Minority Interest: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RIM Gensight Biologics SA LTS:0RIM
14 GF Score
Price €0.11
GF Value €0.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gensight Biologics Minority Interest?

Gensight Biologics LTS:0RIM -0.37% 14 Minority Interest is €0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0RIM with a GF Score™ of 14/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Gensight Biologics's minority interest for the quarter that ended in Dec. 2025 was €0.00 Mil.

Gensight Biologics Minority Interest Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Minority Interest Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gensight Biologics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.00 0.00 0.00 0.00
LTS:0RIM
14GF Score
Gensight Biologics SA LTS:0RIM
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gensight Biologics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Gensight Biologics (LTS:0RIM) has a Minority Interest of €0.00 Mil as of Dec. 2025. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Gensight Biologics.
Is Gensight Biologics' Minority Interest too high?
Gensight Biologics' current Minority Interest is €0.00 Mil. Overall, Gensight Biologics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gensight Biologics' Minority Interest compare to VRTX and REGN?
Gensight Biologics' Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Gensight Biologics. Gensight Biologics's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (LTS:0RIM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.11 — trading 174.5% above its estimated fair value. The current Minority Interest is €0.00 Mil. Gensight Biologics' overall GF Score™ is 14/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Gensight Biologics (LTS:0RIM), the current Minority Interest is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gensight Biologics (LTS:0RIM) Overvalued in 2026?

Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued. The current stock price of €0.11 is trading 174.5% above its estimated GF Value™ of €0.04. GuruFocus considers Gensight Biologics to be Significantly Overvalued.

Key valuation signals for LTS:0RIM:

  • Minority Interest: €0.00 Mil
  • GF Value™: €0.04 vs. price of €0.11 (174.5% above fair value)
  • GF Score™: 14/100 with 8 warning signs

No single metric tells the full story. See the LTS:0RIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
GenSight Biologics SA is a clinical-stage French biopharmaceutical company that develops gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Its pipeline is built on two core technology platforms: mitochondrial targeting sequence (MTS) and optogenetics. The lead product candidate, LUMEVOQ (lenadogene nolparvovec), uses the MTS platform and is designed to treat Leber hereditary optic neuropathy (LHON) by restoring mitochondrial function in retinal ganglion cells; it has been submitted for regulatory review in Europe. The optogenetics program, GS030, aims to restore vision in patients with retinitis pigmentosa through a gene therapy combined with a light-stimulating medical device. The company is headquartered in Paris, France, and conducts clinical development internationally. As a clinical-stage business, GenSight has no marketed products and depends on equity financing, partnerships, and grant funding to advance its pipeline.
14GF Score

Get the complete analysis for LTS:0RIM

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.04
GF Value